心脏移植受者心原性休克的多中心队列研究
该回顾性多中心研究纳入145例心脏移植后≥1月发生心原性休克的受者,评估其预后及1年无事件生存预测因素。1年无事件生存率仅25%,独立预测因素包括CAV≥2级、ICU入住时需肾脏替代治疗、SCAI分期≥D及心肺复苏中启动ECMO。匹配分析显示心脏移植受者VA-ECMO后90天生存率低于急性心梗所致心原性休克患者(22% vs 55%),但与其它免疫抑制患者无显著差异(28% vs 42%)。
要点
- 心脏移植后心原性休克1年无事件生存率仅25%,预后极差。
- CAV≥2级、肾脏替代治疗、SCAI≥D及心肺复苏中启动ECMO是独立预测因素。
- 心脏移植受者VA-ECMO后90天生存率低于匹配的AMICS患者(22% vs 55%)。
核心结论
- 心脏移植后发生心原性休克的患者预后极差,1年无事件生存率仅25%。
- 心脏移植受者接受VA-ECMO的90天生存率低于匹配的AMICS患者,但与其它免疫抑制患者无显著差异。
研究设计与样本
- 回顾性多中心队列研究,纳入2006年6月至2024年8月期间ICU收治的心脏移植后≥1月发生心原性休克的受者145例。
- 主要终点为1年生存且无需再次移植或长期循环支持;接受VA-ECMO的受者与两个外部ECMO队列进行倾向性评分匹配比较。
主要发现
- 休克主要病因为移植心脏排斥反应(51%)、冠状动脉移植血管病变(19%)及其他原因(30%),不同病因间生存率无显著差异。
- 1年无事件生存率为25%。
- 独立预测因素包括CAV≥2级(HR 2.4;95%CI 1.6-3.7)、ICU入住时肾脏替代治疗(HR 1.9;95%CI 1.2-3.1)、SCAI分期≥D(HR 3.6;95%CI 2.1-6.3)及心肺复苏中启动ECMO(HR 2.5;95%CI 1.5-4.1)。
- 匹配分析中,心脏移植受者VA-ECMO后90天生存率显著低于AMICS患者(22% vs 55%),但与其它免疫抑制非移植患者无显著差异(28% vs 42%)。
临床怎么用
- 对心脏移植后心原性休克患者应评估CAV分级、SCAI分期及器官功能,识别高危人群。
- 需肾脏替代治疗或心肺复苏中启动ECMO提示预后更差,应强化治疗决策与资源分配。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study aimed to evaluate the prognosis of heart transplant recipients (HTR) with graft failure-related cardiogenic shock (CS), identify predictors of 1-year event-free survival, and compare their outcomes to those of patients with other CS etiologies. METHODS: This retrospective multicenter study included all HTR admitted to the ICU between June 2006 and August 2024 for CS occurring ≥ 1 month after transplantation. The primary endpoint was 1-year survival, without retransplantation or long-term circulatory support. HTR receiving VA-ECMO were compared with propensity score matching to 2 external ECMO control cohorts: (1) patients with CS due to acute myocardial infarction (AMICS); and (2) immunocompromised patients with CS from various causes. RESULTS: Among the 145 HTR included, the primary causes of shock were cardiac allograft rejection (51%), coronary allograft vasculopathy (19%), and other causes (30%), with no significant differences in survival across etiologies. Event-free survival was 25% at one year. Independent predictors of 1-year event-free survival included CAV grade ≥2 (HR 2.4; 95% CI, 1.6-3.7), renal replacement therapy at ICU admission (HR 1.9; 95% CI, 1.2-3.1), SCAI stage of cardiogenic shock ≥ D (HR 3.6; 95% CI 2.1 to 6.3), and ECMO initiated on cardiopulmonary resuscitation (HR 2.5; 95% CI, 1.5-4.1). In a matched analysis of VA-ECMO patients, heart transplant recipients had significantly lower 90-day survival than matched AMICS patients (22% vs 55%), whereas survival was not significantly different when compared with other immunocompromised non-transplant patients (28% vs 42%). CONCLUSION: CS occurring after heart transplantation is associated with very poor outcomes, with only one quarter of patients free from death, retransplantation, or durable mechanical circulatory support at 1 year. While prognosis appeared worse than in matched patients with AMICS requiring VA-ECMO, outcomes did not significantly differ from those of other immunocompromised patients receiving the same support.
引用
- Harba C, David-Papadopoulos A, Frering A, et al. Cardiogenic shock in heart transplant recipients: A multicenter cohort study with matched analysis. J Heart Lung Transplant. 2026. PMID: 42001917. doi:10.1016/j.healun.2026.03.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。